Overview

A Study to Evaluate Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Status:
Not yet recruiting

Trial end date:
2027-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Carboplatin
Etoposide
Ifosfamide
Obinutuzumab
Rituximab